Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125792652 | 12579265 | 2 | F | 20160623 | 20160809 | 20160721 | 20160811 | EXP | AR-BAYER-2016-138047 | BAYER | 71.00 | YR | E | M | Y | 0.00000 | 20160811 | CN | AR | AR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125792652 | 12579265 | 1 | PS | NEXAVAR | SORAFENIB | 1 | Oral | DAILY DOSE 800 MG (4 DF QD) | 21923 | 800 | MG | FILM-COATED TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125792652 | 12579265 | 1 | Hepatocellular carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125792652 | 12579265 | OT |
| 125792652 | 12579265 | DS |
| 125792652 | 12579265 | DE |
| 125792652 | 12579265 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125792652 | 12579265 | Cardio-respiratory arrest | |
| 125792652 | 12579265 | Hepatocellular carcinoma | |
| 125792652 | 12579265 | Metastases to central nervous system | |
| 125792652 | 12579265 | Mobility decreased | |
| 125792652 | 12579265 | Muscular weakness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125792652 | 12579265 | 1 | 20160328 | 20160718 | 0 |